Progress in the study of antibody-drug conjugates for the treatment of cervical cancer

被引：0
|
作者：
Zhai, Congcong [1 ,2 ]
Cui, Yan [3 ]
Guo, Ling [1 ]
Chen, Cixiang [1 ]
Song, Yanfang [2 ]
Zhong, Jinghua [2 ,4 ]
Wang, Yili [2 ]
机构：
[1] Gannan Med Univ, Dept Oncol, Ganzhou, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Ganzhou, Peoples R China
[3] Bengbu Med Univ, Dept Oncol, Luan, Peoples R China
[4] Gannan Med Univ, Gannan Innovat & Translat Med Res Inst, Ganzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金：
中国国家自然科学基金;
关键词：
antibody-drug conjugates; cervical cancer; targeted therapy; clinical research; drug development; TRASTUZUMAB DERUXTECAN; RECURRENT; EFFICACY; TUMORS; ADC; CHEMOTHERAPY; BEVACIZUMAB; DS-8201A; SAFETY;
D O I：
10.3389/fonc.2024.1395784
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cervical cancer is the second most prevalent malignancy affecting women's health globally, and the number of morbidity and mortality from cervical cancer continues to rise worldwide. The 5-year survival rate of patients with recurrent or metastatic cervical cancer is significantly reduced, and existing treatment modalities have low efficacy and high adverse effects, so there is a strong need for new, effective, and well-tolerated therapies. Antibody-drug conjugates (ADCs) are a new targeted therapeutic modality that can efficiently kill tumor cells. This review aims to summarize the composition, research, and development history and mechanism of action of ADCs, to review the research progress of ADCs in the treatment of cervical cancer, and to summarize and prospect the application of ADCs.
引用
收藏
页数：12
相关论文
共 50 条
  • [21] Antibody-Drug Conjugates for Cancer Therapy
    Parslow, Adam C.
    Parakh, Sagun
    Lee, Fook-Thean
    Gan, Hui K.
    Scott, Andrew M.
    [J]. BIOMEDICINES, 2016, 4 (03)
  • [22] Antibody-drug conjugates for cancer therapy
    Thomas, Anish
    Teicher, Beverly A.
    Hassan, Raffi T.
    [J]. LANCET ONCOLOGY, 2016, 17 (06): : E254 - E262
  • [23] Antibody-Drug Conjugates in Cancer Therapy
    Sievers, Eric L.
    Senter, Peter D.
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 64, 2013, 64 : 15 - 29
  • [24] Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
    Liang, Yan
    Zhang, Purong
    Li, Feng
    Lai, Houyun
    Qi, Tingting
    Wang, Yixin
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [25] In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer
    Xie, HS
    Blättler, WA
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (03) : 281 - 291
  • [26] A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
    Kim, Jung Hoon
    Chang, In Ho
    [J]. INVESTIGATIVE AND CLINICAL UROLOGY, 2022, 63 (04) : 373 - 384
  • [27] Clinical perspective: Antibody-drug conjugates for the treatment of breast cancer
    Najminejad, Zohreh
    Dehghani, Fatemeh
    Mirzaei, Yousef
    Mer, Ali Hussein
    Saghi, Seyyed Amirreza
    Abdolvahab, Mohadeseh Haji
    Bagheri, Nader
    Meyfour, Anna
    Jafari, Ameneh
    Jahandideh, Saeed
    Gharibi, Tohid
    Amirkhani, Zahra
    Delam, Hamed
    Mashatan, Noushin
    Shahsavarani, Hosein
    Abdollahpour-Alitappeh, Meghdad
    [J]. MOLECULAR THERAPY, 2023, 31 (07) : 1874 - 1903
  • [28] Antibody-drug conjugates-an emerging class of cancer treatment
    Diamantis, Nikolaos
    Banerji, Udai
    [J]. BRITISH JOURNAL OF CANCER, 2016, 114 (04) : 362 - 367
  • [29] Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
    Deng, Shanshan
    Lin, Zongtao
    Li, Wei
    [J]. CURRENT MEDICINAL CHEMISTRY, 2017, 24 (23) : 2505 - 2527
  • [30] Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer
    Sato, Sho
    Shoji, Tadahiro
    Jo, Ami
    Otsuka, Haruka
    Abe, Marina
    Tatsuki, Shunsuke
    Chiba, Yohei
    Takatori, Eriko
    Kaido, Yoshitaka
    Nagasawa, Takayuki
    Kagabu, Masahiro
    Baba, Tsukasa
    [J]. CANCERS, 2024, 16 (14)
12345